TrialNCT07567846
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1, PHASE2
- Last update posted
- 09/04/2026
- Start
- 04/29/2026
- Sponsor
- Genentech, Inc.
- Specialties
- oncology
Conditions: Advanced Prostate Cancer; Metastatic Prostate Cancer
Brief summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.